VCM
CRVS icon

Versant Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Versant Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418 Hold
28
– – ﹤0.01% 2698
2026
Q1 		$410 Buy
+28
New +$447 ﹤0.01% 2732

Other funds holding CRVS

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
JSC
Jackson Square Capital San Francisco, California $719M AUM 144.18% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AIM
Avity Investment Management Greenwich, Connecticut $1.57B AUM 35.56% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Versant Capital Management's CRVS Position: Q2 2026 in Review

Versant Capital Management held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 28 shares worth $418. The position accounts for ﹤0.01% of the portfolio, ranked #2698.

Versant Capital Management first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Versant Capital Management held 28 shares of Corvus Pharmaceuticals worth $418 as of Q2 2026.
  • Versant Capital Management left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2698 holding.
  • Versant Capital Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.